Related references
Note: Only part of the references are listed.BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
Valkal Bhatt et al.
PHARMACOTHERAPY (2014)
Ibrutinib for B cell malignancies
Aileen Novero et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2014)
Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)
Jianlin Qiao et al.
BLOOD (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
James E. Neffendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
Marie-Pierre Gratacap et al.
BLOOD (2009)
Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo
Junling Liu et al.
BLOOD (2006)
X-linked Agammaglobulinemia - Report on a United States registry of 201 patients
Jerry A. Winkelstein et al.
MEDICINE (2006)
Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine kinase Syk and phospholipase Cγ2 at distinct sites
K Suzuki-Inoue et al.
BIOCHEMICAL JOURNAL (2004)
Tec regulates platelet activation by GPVI in the absence of Btk
BT Atkinson et al.
BLOOD (2003)
Share Paper
